In Europe, there is a biotechnology company with a market value exceeding Bayer and most established pharmaceutical companies outside of Novo Nordisk. This company has been established for less than 20 years and only has one commercial product in its hands - it is called Argenx.

With its only commercially available drug, efgartigimod (trade name: Vyvgart) ®）， This Dutch based company has maintained a market value of over $50 billion for most of this year and has become one of the most valuable biotechnology companies in Europe.

The latest financial report shows that in Q2 2026, Aijiamod's global net sales reached $1.5 billion, a year-on-year increase of 60% and a month on month increase of 17%. This is its 18th consecutive quarter of growth. In the first half of 2026, Aijiamod's cumulative sales have reached 2.8 billion US dollars.

Based on this trend, Argenx predicts that the sales of Agamod will reach $6 billion by 2026 as the product continues to increase in volume. Multiple investment banks predict that its sales peak is expected to exceed $10 billion - despite the fact that this drug has only been on the market for five years.

Perhaps placed on a longer timeline in Argenx, this narrative rhythm is not unfamiliar.

This company has already written a legendary rise in the pharmaceutical industry: it was founded in 2008, and in 2021, Aijiamod was approved for market by the FDA, and in the same year, it launched independent commercialization; Formally joining the "Billion Dollar Molecule" club in 2023; In 2025, global net sales surged by 90% to $4.151 billion, placing Argenx among the top 50 pharmaceutical companies worldwide.

Why should a company that has only one commercial product on its product list for a long time, with a market value exceeding that of a group of century old pharmaceutical companies? What insights can Argenx's rise provide for China's biotech industry, which is entering the commercialization stage?

01. The birth of the world's first FcRn targeted drug

The starting point of Argenx is not FcRn targets or Vyvgart molecules, but rather an antibody technology platform.

In 2008, Argenx was officially established in the Netherlands based on the SIMPLE ANTIBODY antibody platform. This platform obtains antibody variable regions from the immune system of distantly bred American camels, helping to screen for optimal antibody candidate molecules targeting complex disease targets.

At the beginning, Argenx's research and development direction was not limited to autoimmune diseases, but also included tumor immunity. A series of pipelines were developed, including IL-6 antibody Gerilimzumab, CD70 antibody ARGX-110, c-Met antibody ARGX-111, and IL-22R1 antibody ARGX-112.

In addition to self research, Argenx's antibody platform has also become a favored target for many large pharmaceutical companies, and has successively partnered with Eli Lilly and others Shire、 Bayer and others have reached a cooperation in antibody research and development.

At the same time, Argenx has continuously expanded its "toolbox" and authorized the introduction of a series of Fc engineering modification technologies to precisely regulate the interaction between antibodies and the immune system, optimize molecular half-life, effector function, and tissue targeting ability, and enhance antibody molecular performance.

The turning point occurred in 2014. At that time, Professor Sally Ward's team from the University of Texas Southwestern Medical Center, in collaboration with Argenx, revealed the complete biological mechanism by which FcRn regulates IgG homeostasis and utilized ABDEG ™ Technical evidence shows that a set of targeted amino acid mutations can accelerate IgG degradation in animals.

Argenx is keenly aware that the FcRn IgG pathway provides a new therapeutic window for a large class of pathogenic IgG mediated autoimmune diseases - without the need to clear B cells, only accelerating the clearance of pathogenic antibodies in the circulation.

In fact, before Aijiamod, researchers had attempted to intervene in FcRn through blocking peptides, Fc fragment fusion proteins, and other methods, but none of them were successful.

Argenx through ABDEG ™ The technology has undergone genetic engineering modification to enhance the binding affinity and targeted binding ability with FcRn, thereby reducing the recycling and reuse of IgG, promoting IgG degradation, and achieving the downregulation of immunoglobulin IgG levels - the Agamod (R&D code ARGX-113) project has been officially launched.

In September 2015, the first phase I clinical trial of the drug was launched. In 2017, a phase II study on the treatment of systemic myasthenia gravis (gMG) was successful. That same year, Argenx listed on NASDAQ at $17 per share, with a total market value of $600 million on the first day of its IPO.

The key turning point came in 2020. After six years of research and development, on May 26, 2020, Argenx announced that the global phase III ADAPT trial of Aigamode achieved positive top line results on the first indication gMG, becoming the first FcRn inhibitor to demonstrate significant efficacy.

Data shows that among acetylcholine receptor antibody positive (AChR Ab+) patients, 67.7% of patients in the Aigamimod treatment group achieved the primary endpoint of MG-ADL score, while only 29.7% in the placebo group (p<0.0001). In addition, 63.1% of patients in the treatment group responded on the QMG score, compared to only 14.1% in the placebo group.

Based on these results, on December 17, 2021, Aijiamod was officially approved for market by the FDA (trade name Vyvgart) ®）， Used for adult systemic myasthenia gravis, which accounts for approximately 85% of all gMG patients.

Tim Van Hauwermeiren, co-founder and then CEO of Argenx, called this day the "beginning of a new era for Argenx and the gMG community" - it was the company's first approved product, the first FcRn blocker, and the first approved therapy aimed at reducing pathogenic IgG.

This dormant period reveals a truth: the explosion of biotechnology companies is never accidental, but the inevitable result of long-term accumulation. Argenx relies on its technology platform to deeply cultivate the basic capabilities of antibody engineering and Fc regulation. When the biological opportunities of FcRn arise, this company happens to have the complete toolbox to transform it into drugs.

In addition, the efficient connection between academia and industry is also one of Argenx's core competencies.

Through the Immunology Innovation Program (IIP), Argenx has established a long-term collaborative network with top global research institutions and academia. IIP, as the company's new drug discovery engine, operates for a long time, identifying potential targets from emerging biological mechanisms and continuously transforming them into pipeline candidate drugs. This open innovation model anchors it to the forefront of science.

02. The Rise of Self Exemption Bulk Products

After the product was approved for market launch, Argenx almost started the double speed mode.

In 2022, the first full sales year, the sales revenue of Agamod reached 400 million US dollars. Since then, it has been rising year by year: surpassing 1 billion in 2023, reaching 2.2 billion in 2024, jumping to 4.15 billion US dollars in 2025 (a year-on-year increase of 90%), and reaching 2.81 billion US dollars in the first half of 2026.

The strong sales of Agamod have driven Argenx to achieve its first full year operating profit in 2025, with a net profit of $1.29 billion and an operating profit of $1.05 billion. Over the past five years, Argenx's stock price has skyrocketed to around $1000 per share, and its market value has also risen to around $60 billion today.

This achievement is supported by the fundamental factors of the huge treatment demand in the field of immunotherapy, as well as the return on Argenx's precise investment in clinical development and commercialization.

Prior to its official launch, Argenx had already started recruiting a sales team and building a commercial team in advance to ensure that the product could quickly expand after its launch. At the same time, the company has rapidly expanded its coverage through partnerships, such as collaborating with Zaiding Pharmaceutical to promote development and commercialization in Greater China, while also covering other international markets through partners such as Medison and GenPharma.

Of course, the real moat lies in the product itself. Argenx has truly achieved the compound interest extension of the "Pipe-in-a-Product" through a development strategy that combines depth and breadth.

Karen Massey, the current CEO of Argenx, positions Aegamode as the K-drug in the field of autoimmunity. In an interview, she bluntly stated, "Vyvgart is a once-in-a-generation asset. Similar to Keytruda, it serves as a foundational therapy that allows us to build upon it. There are approximately 100 different indications or diseases that may be treated with Vyvgart, so we are constantly exploring the areas where it can have an impact on patients. ”

This is precisely the strategic core of Argenx - not just one drug, but building a "K-drug" platform in the field of immunity with the FcRn mechanism as the anchor point.
Along this path, the indications for Agamod have rapidly expanded over the past five years: chronic inflammatory demyelinating polyneuropathy (CIDP) was approved in 2024; In 2026, the scope of application has been expanded to remove restrictions on AChR antibody positivity, covering all gMG patient populations.

Not long ago, positive results were achieved in the Phase III clinical trial of Aigamimod in autoimmune myositis, which is also the world's first Phase III trial to achieve positive results in immune-mediated necrotizing myopathy (IMNM). Previously, IMNM was drug free and had commercial potential comparable to myasthenia gravis, paving the way for Aigamimod to be approved in another major disease field.

In addition to expanding indications, dosage form iteration is also crucial. The subcutaneous injection type will be approved in 2023, and the administration time will be shortened from 1 hour for intravenous injection to 20-30 seconds; Pre filled syringes will be launched in 2025, adding a third administration method that allows patients to self inject, further improving patient compliance and medication accessibility.

In the past, the lifecycle of a new drug often relied on the next generation of products to take over; And Argenx provides another approach - to "fully exploit" a drug around the same mechanism, the wider the indications, the more reusable the clinical and commercial infrastructure built in the early stages, and the higher the efficiency.

According to the development progress, the key data for Aijiamod will be read out next, including the top line results of the ADVANCE-NEXT trial for primary immune thrombocytopenia (ITP) expected to be announced in the first half of 2027, and the top line results of the UNITY trial for SjD expected to be read out in the second half of 2027.

Massey stated in an interview that Argenx is still "primarily a 'Vyvgart story'" in the eyes of most people, and this situation is unlikely to change in the short term.
But according to Argenx's grand plan, Aigamimod may not only be used as a monotherapy, but also as a "backbone" drug for combination therapy, combined with multiple therapies - just like Keytruda's application in the field of cancer.

03. Copy the next Agamod

Of course, Agamod's success is just the starting point.

Argenx has proposed the "Vision 2030" strategy: by 2030, treat 50000 patients worldwide, obtain 10 approved indications, and advance 5 pipeline candidate drugs to registered clinical development.

The three core driving forces for achieving this vision are: building winning molecules, entrepreneurial clinical development, and providing differentiated patient experiences.
Regarding the first point, Argenx is systematically building the second and third growth curves around its core immunology capabilities

Empasiprubart: a pioneering antibody targeting complement C2, has undergone three phase III trials in multifocal motor neuropathy (MMN) and CIDP, with MMN data expected to be available in the fourth quarter of 2026.

Adimanebart (ARGX-119): The first excitatory antibody targeting MuSK has entered phase III development of congenital myasthenia gravis syndrome (CMS) and is being explored in spinal muscular atrophy.

ARGX-213 and ARGX-124: a new generation of FcRn molecules, the former has the conditions to enter phase III and aims to cover indications where Vyvgart has not yet fully penetrated.

ARGX-121: Anti IgA antibody for IgA nephropathy, phase II study expected to commence in 2026.

Self research cannot avoid the cost of time, as new targets can take several years from early molecular stages to clinical endpoints. To quickly fill the gap in capabilities, mergers and acquisitions have become a pragmatic choice, especially for Argenx, which holds $5.2 billion in cash.

In July 2026, Argenx announced the acquisition of Nasdaq listed Forte Biosciences for $77 per share, with an overall equity value of approximately $2.2 billion. One month later, the transaction was officially completed and delivered.

This is a highly controversial transaction, with an overall premium of 86%, coupled with Forte's own dramatic story: several years ago, the company was almost on the brink of liquidation, and after the failure of its main live action drug Phase II in 2021, its stock price plummeted by 80%, with major shareholders even publicly proposing liquidation.
But in fact, this acquisition had already laid the groundwork: in April 2026, Argenx had already participated in Forte's financing, investing $150 million.

Argenx is truly interested in FB102, a pioneering anti-CD122 antibody in its class. This target inhibits inflammatory responses related to activated T cells, memory T cells, and NK cells by regulating the IL-12/IL-15 signaling pathway, while retaining the supportive effect of the IL-2/CD25 pathway on Treg cells, achieving more precise and safe immune regulation.

FB102 has obtained clinical concept validation in two indications, vitiligo and celiac disease, and has the potential to expand to various autoimmune diseases such as alopecia areata.

From a strategic logic perspective, FB102 is highly similar to Agamod.

On the one hand, both are pioneering assets in the field of immunology - Aigamimod is the world's first FcRn antagonist, opening up a new therapeutic direction for targeting pathogenic IgG; FB102 is one of the world's first innovative antibodies targeting CD122, and has been validated clinically feasible in the IL-12/IL-15 pathway.

On the other hand, both have the potential for a "pipeline in a-product" platform - Aijiamod started from gMG and has now expanded to 15 indications; FB102 also has the potential to expand into multiple disease domains due to its broad involvement in T cell and NK cell abnormal activation in various autoimmune diseases.

In other words, Argenx aims to replicate FB102 as the 'next Egamond' by leveraging its clinical development capabilities and commercial execution capabilities accumulated in the FcRn field. This is not simply 'buying products', but using a validated capability framework to leverage a new biological asset that has not yet fully unleashed its value.

— In Conclusion —

Upon closer examination, the rise of Argenx is the product of strategic choices at every step - from early platform accumulation, to betting on the broad-spectrum pathway of FcRn, to systematic expansion around the "pipeline-in-a-product" logic.

Interestingly, in the recent interview with Karen Massey, the new CEO, she spent the most time discussing neither Agamod's sales figures nor the next blockbuster product, but a seemingly "vague" term: culture.

In Massey's description, Argenx possesses a "punk rock" vibe internally - it eschews the top-down, departmentalized processes typical of traditional pharmaceutical giants, instead integrating different functional teams for research and development, clinical trials, and commercialization based on indications, allowing those who seek new science and those who engage with patients to work together in the same trenches.

In her words, this system "actively challenges the hierarchical systems and bureaucracy often found in large corporations" and offers a solution to the seemingly intractable problem in the biotech sector: how to preserve the entrepreneurial spirit and agility of a startup as the company expands from a small scale to a large enterprise.

Massey is keenly aware of this. She believes that the two things that are most prone to problems during the scaling stage are arrogance and bureaucracy, red tape, and departmental silos.
Therefore, she repeatedly emphasized the "Argenx Way", "which is our way of working. We regard it as a competitive advantage that allows us to run faster and continue to innovate."

This may be the most intriguing footnote in the Argenx story. People often attribute the success of biotech companies to "hitting the target" or "catching the wave", but what truly sustains a company's continued progress is often not making the right choices at the right time, but rather how it combats arrogance and bureaucracy during its expansion.

References:
1.argenex Q2 Earnings Call Highlights
2.PharmaVoice，Q&A：A single drug made Argenx one of the most valuable biotechs in Europe. Its new CEO is ready for the next act.
3.Fierce Pharma，Argenx heads to FDA with Vyvgart after ph. 3 win in potential blockbuster autoimmune indication
4.BioPharma Dive，Argenx jumps on Phase 3 data for blockbuster Vyvgart
5. Pharmaceuticals in Perspective: A $2.2 Billion Acquisition: Argenx's Transformation from a Single Blockbuster Drug to an Immunotherapy Platform
6. Amino Watch, firing the first shot in mergers and acquisitions, with a "new buyer" emerging in the autoimmune track
7. How does Pharmaceutical Cube, a First-in-Class drug, become the world's youngest MNC